In the wake of increased clinical deaths in India, regulations on the lines suggested in the article, “ >A steel frame for clinical trials ” (Oct. 8), are necessary. Together with amendments in the Drugs and Cosmetics Act, making it mandatory for the principal investigator of the pharma company to reveal the contract between the subject and the company to the DGCI, it will help usher in an era of transparency. The issue of adequate compensation for victims needs to be addressed.
Arun Vijayan,
Thiruvananthapuram
